{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T16:10:09Z","timestamp":1748794209429,"version":"3.41.0"},"reference-count":14,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T00:00:00Z","timestamp":1463961600000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biopharm &amp; Drug Disp"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Purpose<\/jats:italic>: Some reports have suggested that bucolome, an inhibitor of cytochrome P450 2C9, is useful for decreasing inter\u2010patient variation in warfarin clearance. The purpose of the present study was to evaluate the utility of the concomitant administration of bucolome and warfarin using an in<jats:italic>silico<\/jats:italic>approach.<jats:italic>Methods<\/jats:italic>:<jats:italic>In vitro<\/jats:italic>data regarding the enzymatic kinetics of (<jats:italic>S<\/jats:italic>)\u2010warfarin and bucolome were collected from the literature. As a validation study, the geometric mean (GM) of the oral unbound clearance of (<jats:italic>S<\/jats:italic>)\u2010warfarin and its inter\u2010patient variation (assessed using the standard deviation of its natural logarithm (\u03c3)) were predicted using a physiologically based population pharmacokinetic simulator (Simcyp<jats:sup>TM<\/jats:sup>) and compared with clinical data. The utility of the concomitant administration was evaluated by comparing the GM and \u03c3 values predicted under various conditions (the prediction study).<jats:italic>Results and Discussion<\/jats:italic>: The \u03c3 values in the presence and absence of bucolome were predicted to be 0.73 and 0.68, respectively, suggesting that bucolome might increase the inter\u2010patient variation, as clinically observed. In the prediction study, the \u03c3 value of the bucolome co\u2010administered group was greater in almost all of the examined conditions. In conclusion, the concomitant administration of bucolome might not be useful for reducing the inter\u2010patient variation of (<jats:italic>S<\/jats:italic>)\u2010warfarin pharmacokinetics. Copyright \u00a9 2016 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/bdd.2008","type":"journal-article","created":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T08:47:24Z","timestamp":1456822044000},"page":"233-242","source":"Crossref","is-referenced-by-count":3,"title":["<i>In silico<\/i>evaluation of warfarin\u2013bucolome therapy"],"prefix":"10.1002","volume":"37","author":[{"given":"Hisakazu","family":"Ohtani","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacy Keio University Faculty of Pharmacy, 1\u20105\u201030 Shibakoen Minato\u2010ku Tokyo 105\u20108512 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Hakoda","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacy Keio University Faculty of Pharmacy, 1\u20105\u201030 Shibakoen Minato\u2010ku Tokyo 105\u20108512 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayuko","family":"Imaoka","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacy Keio University Faculty of Pharmacy, 1\u20105\u201030 Shibakoen Minato\u2010ku Tokyo 105\u20108512 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Akiyoshi","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacy Keio University Faculty of Pharmacy, 1\u20105\u201030 Shibakoen Minato\u2010ku Tokyo 105\u20108512 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,5,23]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140080-00003"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2004.12.009"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-10-0842"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.51.399"},{"key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0090-9556(24)15043-X","article-title":"Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of in vitro approaches to predicting in vivo reduction of (S)\u2010warfarin clearance","volume":"27","author":"Takahashi H","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.19.869"},{"key":"e_1_2_7_8_1","first-page":"306","volume-title":"Statistical Methods in Medical Research","author":"Armitage P","year":"2001"},{"key":"e_1_2_7_9_1","unstructured":"Paramidin Asuka Pharmaceuticals Japan.Interview\u2010form (drug information booklet) (Ver 8) (in Japanese)2015. (available fromhttp:\/\/www.info.pmda.go.jp\/go\/interview\/2\/470007_1149009M1035_2_V08_1F)"},{"key":"e_1_2_7_10_1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1248\/yakushi1947.86.9_739","article-title":"Binding of 1\u2010\u2009cyclohexyl\u20105\u2010n\u2010butyl\u20102,4,6\u2010trioxoperhydropyrimidine with serum albumin","volume":"86","author":"Kakemi K","year":"1996","journal-title":"Yakugaku Zasshi"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.129321"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2003.26a"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010370588"},{"key":"e_1_2_7_14_1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0090-9556(25)07369-6","article-title":"Warfarin\u2010fluconazole. II. A metabolically based drug interaction: in vivo studies","volume":"24","author":"Black DJ","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.8.1043"}],"container-title":["Biopharmaceutics &amp; Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdd.2008","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.2008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T15:40:44Z","timestamp":1748792444000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.2008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1002\/bdd.2008"],"URL":"https:\/\/doi.org\/10.1002\/bdd.2008","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"type":"print","value":"0142-2782"},{"type":"electronic","value":"1099-081X"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}